Alcoholic liver disease: a modern look at diagnosis and treatment

 Alcohol is one of the leading etiological factors in liver damage. In alcoholic liver disease (ALD), hypoxia occurs due to an imbalance between the energy requirement of hepatocytes and energy production in the mitochondrial oxidative phosphorylation system. Diagnosis of ALD includes the taking of an anamnesis, questioning of patients, clinical examination data, laboratory and instrumental study. For the treatment of ALD, agents are used that protect cell membranes from oxidative stress factors and restore the energy potential of cells under conditions of tissue hypoxia. One such hepatotropic infusion is Remaxol®, the original polyionic succinatemethionine complex based on succinic acid. Aim of the study: to consider the effects of using Remaxol® infusion drug in the group of ALD patients. Materials and methods: treatment of 40 patients (male) with ALD was carried out, all of whom had a distinct history of the disease with regular and prolonged alcohol abuse. The duration of the disease in the group was 4.8 ± 0.7 years. Initially, all of them showed increased lipid peroxidation, depression of antioxidant protection, as well as pronounced sings of cytolysis, cholestasis and lipid metabolism. Then, all patients in the group were treated with Remaxol®. The course of treatment ranged from 5 to 10 daily intravenous drip infusions. After treatment, the parameters of lipid peroxidation malondialdehyde (MDA), diene conjugates (DC), enzymes of antioxidant system catalase (Cat), superoxide dismutase (SOD), glutathione peroxidase (GP), markers of cytolysis, cholestasis and lipid metabolism were again investigated in the serum of patients. Results of the study: a positive effect after monotherapy with Remaxol® was observed in 34 patients, which amounted to 85% of the group. They recorded a significant decrease in lipid peroxidation and a compensatory increase in antioxidant system enzymes. The indicators of cytolysis and cholestasis syndromes significantly decreased, lipid metabolism was restored, and the subjective status of patients improved. There were no side effects during the treatment with Remaxol® in the group of patients with ALD. Conclusions: It was noted that therapy with Remaxol® caused positive laboratory dynamics in 34 patients, which amounted to 85% of all treated patients with ALD. Thus, it has been shown that therapy with Remaxol® is an effective method of treating alcoholic liver disease.

1. Shilov V.V., Vasiliev S.A., Shikalova I.A., Butotsyrenov B.V. Features of the pharmacological correction of toxic hepatopathy in severe forms of acute alcohol poisoning against the background of prolonged abuse (binges). RMZH = RMJ. 2010;(18):1141. (In Russ.) Available at: https://www.rmj.ru/articles/narkologiya/Osobennosti_farmakologicheskoy_korrekcii_toksicheskoy__gepatopatii_pri_tyaghelyh_formah_ostryh_otravleniy__alkogolem_na_fone_dlitelynogo_zloupotrebleniya_zapoev/.

2. Vangorodskaya S.A. The Russian model of alcohol consumption: features and impact on population. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya: Filosofiya. Sotsiologiya. Pravo = Scientific reports of Belgorod State University. Series: Philosophy. Sociology. Right. 2018;(1):28-36. (In Russ.) doi: 10.18413/2075-4566-2018-43-1-28-36.

3. Kostyukevich O.I. Alcoholic hepatitis: modern diagnostic and treatment algorithms. RMZH. Meditsinskoe obozrenie = RMJ Medical Review. 2016;(3):177-182. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/Alkogolynyy_gepatit_sovremennye_algoritmydiagnostiki_i_lecheniya/.

4. Mayev I.V., Abdurakhmanov D.T., Andreev D.N., Dicheva D.T. Alcoholic liver disease: State-oftheart. Terapevticheskiy arkhiv = Therapeutic archive. 2014;(4):108-116. (In Russ.) Available at: https://www.mediasphera.ru/issues/terapevticheskijarkhiv/2014/4/030040-36602014419.

5. Koshkina E.A., Pavlovskaya N.N., Yagudina R.I., Kulikov A.Yu., Usenko K.Yu. Health and social and also economic consequences of alcohol abuse in the Russian Federation. Sotsial’nye aspekty zdorov’ya naseleniya = Social aspects of public health. 2010;(2):1-12. (In Russ.) Available at: https://cyberleninka.ru/article/v/mediko-sotsialnye-i-ekonomicheskie-posledstviyazloupotrebleniya-alkogolem-v-rossii.

6. EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. J Hepatol. 2018;(69):154-181. doi: https://doi.org/10.1016/j.jhep.2018.03.018.

7. Ilchenko L.Yu., Okovity S.B. Remaxol: mechanisms of action and application in real clinical practice. Part 1. Arhiv vnutrennej mediciny = The Russian Archives of Internal Medicine. (In Russ). 2016;6(2):16-21. doi: 10.20514/22266704-2016-6-2-16-21.

8. Baykova I.E., Nikitin I.G., Gogova L.M. Alcoholic Liver Disease. RMZH = RMJ. (In Russ). 2011;(17):1067. Available at: https://www.rmj.ru/articles/bolezni_organov_pishchevareniya/Alkogolynaya_bolezny_pecheni_1/.

9. Cunningham C.C., Van Horn C.G. Energy availability and alcohol – related liver pathology. Alcohol Research & Health. 2003;27(4):291301. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15540800.

10. Leung T.-M., Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol. 2013;(58):395-398. doi: https://doi.org/10.1016/j.jhep.2012.08.018.

11. Mayevskaya M.V., Bakulin I.G., Chirkov A.A., Lyusina Y.O., Lun’kov V.D. Alcohol abuse in gastroenterological patients. Rossijskij žurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(4):24-35. (In Russ.) doi: 10.22416/1382-4376-2016-26-4-24-35.

12. Staufer K., Yegles M. Biomarkers for detection of alcohol consumption in liver transplantation. World J Gastroenterol. 2016;22(14):3725– 3734. doi: 10.3748/wjg.v22.i14.3725.

13. Fialla A.D., Israelsen M., Hamberg O. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int. 2015;35:2072-2078. doi: 10.1111/liv.12798.

14. Suk K.T., Kim M.Y., Baik S.K. Alcoholic liver disease: treatment. World J Gastroenterol. 2014;20(36):12934–12944. doi: 10.3748/wjg.v20.i36.12934.

15. Tilg H., Day C.P. Management strategies in alcoholic liver disease. Nature Clinical Practice Gastroenterology & Hepatology. 2007;4(1):24– 34. doi:10.1038/ncpgasthep0683.

16. Minushkin O.N., Maslovsky L.V., Frolova A.A., Shaposhnikova O.F. The experience of using the drug Metadoxil in patients with alcoholic cirrhosis of the liver. RMZH. Meditsinskoe obozrenie. Gastroehnterologiya = RMJ Medical Review. Gastroenterology. 2013;(19):968. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/Opyt_primeneniya_preparata_Metadoksil_u_bolynyh_alkogolynym_cirrozom_pecheni/.

17. Vinnitskaya E.V., Kiseleva A.V. Alcoholic liver disease in practice of general practitioner. Ehffektivnaya farmakoterapiya. Gastroehnterologiya. Spetsvypusk = Effective pharmacotherapy. Gastroenterology. Special issue. 2014;1(7):22-28. (In Russ.) Available at: http://umedp.ru/articles/alkogolnaya_bolezn_pecheni_v_praktike_terapevta_.html.

18. Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S., Sivolap Yu.P., Lunkov V.D., Zharkova M.S., Maslennikov R.V. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(6):20-40. (In Russ.) Available at: http://rsls.ru/files/ABP_rec.pdf.

19. Eremina E.Yu. Alcoholic liver disease. Part 1. Arkhiv’ vnutrenney meditsiny = Archive of internal medicine. 2012;6(8):50-54. (In Russ.) Available at: https://cyberleninka.ru/article/n/alkogolnaya-bolezn-pecheni-chast-1.

20. Shirokikh A.V., Vyalov S.S. Alcoholic steatosis and chronic alcoholic hepatitis: features of pathogenesis and treatment tactics. Consilium Medicum. Gastroehnterologiya = Consilium Medicum. Gastroenterology. (Adj.) 2013;(1):21-27. (In Russ.) Available at: https://con-med.ru/magazines/gastroenterology/gastroenterology01-2013/alkogolnyy_steatoz_i_khronicheskiy_alkogolnyy_gepatit_osobennosti_patogeneza_i_taktika_lecheniya/.

21. Myazin R.G., Snigur G.L., Emel’yanov D.N., Chernyshova M.V. Pharmacological Correction of Experimental Acute Toxic Hepatitis. Zhurnal anatomii i gistopatologii = Journal of Anatomy and Histopathology. 2019;(1):49-54. (In Russ.) doi: 10.18499/2225-7357-2019-8-1-49-54.

22. Maximov M.L., Shindina T.S., Kropova O.E. Hepatoprotective and infusion therapy in patients with inflammatory liver diseases. RMZH. Meditsinskoe obozrenie = RMJ Medical Review. 2018;7(II):82-87. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/Gepatoprotektornaya_iinfuzionnaya_terapiya_pacientov_svospalitelynymi_zabolevaniyami_pecheni/.

23. Minushkin O.N., Maslovskiĭ L.V., Bukshuk A.A. The use of hepatic protectors in clinical practice. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2012;10(2):67–72. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-skorsakova2/2012/10/downloads/ru/031997729820121030.

24. Minushkin O.N. Hepatoprotectors in the therapy of some hepatic diseases. Meditsinskiy sovet = Medical Council. 2016;(14):52-57. (In Russ.) https://doi.org/10.21518/2079701X-2016-14-52-57.

25. Sukhanov D.S., Okovityi S.V., Yablonskyi P.K., Vinogradova T.I., Pavlova M.V. Hepatotropic Therapy in Treatment of Liver Injury. Antibiotiki i khimioterapiya = Antibiotics and chemotherapy. (In Russ.). 2012;(5-6):41-52. Available at: https://cyberleninka.ru/article/n/gepatotropnayaterapiya-v-lechenii-porazheniy-pecheni.